Publications

Updated publication list June 2022

2022

  1. Baech J, Severinsen MT, Øvlisen AK, Frederiksen H, Vestergaard P, Torp-Pedersen C, Jørgensen JM, Clausen MR, Poulsen CB, Brown P, Gang AO, Pedersen R, Ekström Smedby K, Eloranta S, Hjort Jakobsen LH, El Galaly TC. Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. Blood Adv. 2022 Jun 9:bloodadvances.2021006859. doi: 10.1182/bloodadvances.2021006859. Epub ahead of print. PMID: 35679481.
  2. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF,
  3. Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X. PMID: 35483398.
  4. Petersen MA, Rosenberg CA, Brøndum RF, Aggerholm A, Kjeldsen E, Rahbek O, Ludvigsen M, Hasle H, Roug AS, Bill M. Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups. Br J Haematol. 2022 Mar 17. doi:10.1111/bjh.18094. Epub ahead of print. PMID: 35298835.
  5. Jakobsen LH, Øvlisen AK, Severinsen MT, Bæch J, Kragholm KH, Glimelius I, Gang AO, Jørgensen JM, Frederiksen H, Poulsen CB, Clausen MR, Pedersen PT, Pedersen RS, Torp-Pedersen C, Eloranta S, El-Galaly TC. Patients in complete
  6. remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer J. 2022 Jan 27;12(1):16. doi: 10.1038/s41408-022-00614-8. PMID: 35087026; PMCID: PMC8795387.
  7. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 1;28(5):972-983. doi: 10.1158/1078-0432.CCR-21-2949. PMID: 34980601.
  8. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Young KH. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 Feb 1;12(2):25. doi: 10.1038/s41408-022-00617-5. PMID: 35105854; PMCID: PMC8807629.
  9. Schmidt L, Issa II, Haraldsdóttir H, Hald JL, Schmitz A, Due H, Dybkær K. Hsp90 inhibition sensitizes DLBCL cells to cisplatin. Cancer Chemother Pharmacol. 2022 Feb 21. doi: 10.1007/s00280-022-04407-5. Epub ahead of print.
    PMID: 35190872.
  10. Galsklint J, Kold S, Kristensen SR, Severinsen MT, Gade IL. Validation of Postsurgical Venous Thromboembolism Diagnoses of Patients Undergoing Lower Limb Orthopedic Surgery in the Danish National Patient Registry. Clin Epidemiol. 2022 Feb 17;14:191-199. doi: 10.2147/CLEP.S345293. PMID: 35210866; PMCID: PMC8860350
  11. Eyre TA, Jensen P, Booth S, El-Galaly TC. Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures. Br J Haematol. 2022 Mar 2. doi: 10.1111/bjh.18104. Epub ahead ofprint. PMID: 35235226.
  12. Jensen O, Øvlisen AK, Jakobsen LH, Roug AS, Nielsen RE, Marcher CW, Ebbesen LH, Theilgaard-Mönch K, Møller P, Schöllkopf C, Torp-Pedersen C, El-Galaly TC, Severinsen MT. Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404AML and 1307 MDS Patients. Clin Epidemiol. 2022 Feb 25;14:225-237. doi: 10.2147/CLEP.S336115. PMID: 35241936; PMCID: PMC8887140.
  13. Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B,Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. PMID: 35123422.
  14. Husby S, Jørgensen GØ, Favero F, Jespersen JS, Rodriguez-Gonzalez FG, Nielsen C, Sorensen B, Ebbesen LH, Bæch J, Haastrup EK, Josefsson P, Thorsgaard M, Brown P, El-Galaly TC, Larsen TS, Weischenfeldt J, Grønbæk K. Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT. Bone Marrow Transplant. 2022 Feb 5. doi: 10.1038/s41409-022-01580-2. Epub ahead of print. PMID: 35124694.
  15. Joelsson JK, Wästerlid T, Rosenquist R, Hjort Jakobsen LH, El Galaly TC, Ekström Smedby K, Eloranta S. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 2022 Jan 18:bloodadvances.2021006369. doi: 10.1182/bloodadvances.2021006369. Epub ahead of print. PMID: 35042239.
  16. El-Galaly TC, Villa D, Cheah CY, Gormsen LC. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter? Br J Haematol. 2022 Jan 17. doi: 10.1111/bjh.18016. Epub ahead of print. PMID: 35037240.
  17. Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne MJ, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, Mcilroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O’Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüessmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients. Blood. 2022 Jan 7:blood.2021014506. doi: 10.1182/blood.2021014506. Epub ahead of print. PMID: 34995350.

PHD THESIS

Charles Vesteghem 2022, “30-day mortality of patients with advanced cancer: monitoring and machine learing models using extensive health data”.

Aktivitetsrapport for Relapsprojektet 2015-2020

NEXT Bioinformatics Activity Report 2015-2018

Publications 2021

Publications 2020

Publications 2019

Publications 2018

Publications 2017

Publications 2016

Publications 2015

Publications 2014

Publications 2013

Publications 2012

Publications 2011

Publications 2010 

Publications 2009 – 2004